相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

宫癌中的瘤突变负担作为免疫疗法响应者的潜在标记

Magdalena Ewa Kowalkowska^1,2, Katarzyna Kamińska³, Joanna Wojtysiak³

¹Clinical Department of Oncological Gynecology, Oncology Centre in Bydgoszcz, 85-796 Bydgoszcz, Poland.

|September 27, 2025

概括

瘤突变负担 (TMB) 在宫癌中很常见,不管是什么阶段或亚型. 高的TMB与特定的分子形状和并发症相关,有助于免疫治疗患者的选择.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
生物标志物研究生物标志物研究

背景情况:

瘤突变负担 (TMB) 显示出作为固体瘤免疫治疗生物标志物的前景.
它在宫癌中的重要性需要进一步定义.

研究的目的:

评估宫癌患者的基因组景观和TMB概况.
探索TMB与临床特征,HPV状况和治疗的关联.

主要方法:

对61名宫癌患者的回顾性分析.
针对TMB计算的下一代测序.
与临床和分子变量进行相关性分析.

主要成果:

在59%的患者中观察到高TMB (≥10mut/Mb).
TMB与FIGO阶段,组织学或HPV 16/18没有相关性.
较高的TMB与结节卷入,糖尿病和HPV52感染有关.
PIK3CA和ARID1A经常发生突变.

结论:

高TMB在子宫癌中普遍存在,不管是什么阶段或组织学.
TMB与特定的分子和并发症概况相关.
TMB可能有助于免疫治疗的患者分层.

关键词:

在FIGO中分阶段.这是一个HPVHPVHPV.宫癌:子宫癌是一种癌症.基因组分析是基因组分析.妇科瘤学妇科瘤学免疫治疗的生物标志物这是下一代测序.身体突变是体质突变.有针对性的治疗.瘤突变负担的突变负担

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.